Eye-Opening Phase III Data For AbbVie’s HCV Combo Suggest A Tightened Race
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AbbVie anticipates filing its oral three-drug combination for hepatitis C early in the second quarter after unveiling impressive top-line Phase III data. The Abbott Laboratories spinout said its late-stage pipeline positions the company for strong growth starting in 2015.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.